

BACKGROUND

- The role of vitamin D supplementation on bone health in type 2 diabetes (T2D) is not known.
- The effects of vitamin D supplementation on markers of bone resorption have shown mixed results in normoglycemic adults.¹⁻⁶
- There are scant data on how vitamin D supplementation alters markers of bone resorption in patients with T2D.
- There are no data on the effect of vitamin D supplementation on dynamic changes in markers of bone resorption after a meal.

OBJECTIVES

- To examine the effect of supplementation with 4000 IU/day of vitamin D₃ for 24 weeks on serum CTX levels during fasting and after a 75-g oral glucose tolerance test (OGTT) in patients with early, well-controlled T2D.

METHODS

- Secondary analysis from the DDM2 study (a clinical trial of D₃ supplementation in patients with well-controlled T2D) in a subset of patients managed with lifestyle (placebo [P] n=12) or vitamin D₃ [VD], n=13)
- A 180-min OGTT was performed at baseline and week 24 after supplementation with VD or P.
- Serum was collected at time 0', 15', 30', 60', 90', 120', 150' and 180'.
- Archived samples were analyzed for serum CTX level by electrochemiluminescent immunoassay at Quest Diagnostics, Inc.

RESULTS

Table 1. Baseline variables did not differ in the two groups.

Characteristics	Vitamin D (N=13)	Placebo (N=12)
Age, years	57.5 ± 7.5	61.8 ± 8.3
Female, n (%)	2 (15.4%)	5 (41.7%)
Weight, kg	90.7 ± 17.0	87.5 ± 17.3
Body Mass Index, kg/m ²	29.8 ± 3.9	30.6 ± 4.3
Total 25OHD, ng/mL	24.4 ± 10.8	27.0 ± 12.8
Hemoglobin A1c, %	6.7 ± 0.8	6.7 ± 0.5
Race, n (%)		
White	9 (69.2%)	8 (66.7%)
Black or African-American	2 (15.4%)	3 (25.0%)
Asian	2 (15.4%)	1 (8.3%)
Other		
Ethnicity, n (%) Hispanic or Latino	0 (0.0%)	1 (8.3%)
Fasting CTX, pg/mL	422.9 ± 155.8	368.0 ± 141.0

Values are means ± standard deviation unless otherwise specified;


Percent (%) changes from baseline to week 24 in (a) fasting CTX and in (b) the area under the post-OGTT CTX curve (CTX_{AUC}) did not differ significantly in the two groups (Table 2). Adjustment for baseline CTX level did not significantly alter results (data not shown). Patterns of change during the OGTT are shown in Fig 1.

Table 2. Effects of 24 weeks of vitamin D supplementation on CTX.

	% Change from baseline		P value
	Vitamin D, (N = 13)	Placebo, (N = 12)	
Fasting CTX	-12 ± 27	3 ± 19	0.118
Total AUC _{CTX 1-180}	-10 ± 23	5 ± 16	0.061
Total 25OHD, ng/mL	154.0 ± 27.1	31.5 ± 28.2	0.005

Values are mean ± SEM.


Fig 1. Percent change in serum CTX during OGTT after 24 weeks of vitamin D supplementation.



RESULTS (CONT.)

In the entire cohort, change in 25OHD was inversely associated with % changes in fasting CTX ($r = -0.561$, $p = 0.004$) and in CTX_{AUC} ($r = -0.546$, $p = 0.005$) (Fig 2).

Fig 2. Associations between change in 25OHD and % changes in (2a) fasting CTX and (2b) post-OGTT CTX_{AUC}.



CONCLUSION

- Although fasting and post-OGTT CTX decreased following 24 wks. of vitamin D₃ supplementation as compared to placebo, the differences were not statistically significant in this pilot.
- Increases in 25OHD were significantly associated with reductions in fasting and post-OGTT CTX levels.

These findings suggest that improvements in vitamin D status may lower bone resorption in adults with early T2D; however, larger studies are needed to confirm these preliminary data.

REFERENCES

- Kamel S et al. JCEM 1996;81:3717-21.
- Madar AA et al. Bone Rep 2015;2:82-8.
- Prestwood KM et al. Osteoporos Int 1996;6:314-9.
- Schwetz V et al. Nutrients 2017;9
- Nahas-Neto J et al, Osteoporos Int 2018;29:1125-33.
- Rossini M et al. JCEM 2012;97:E622-6.